Keywords: novartis, seeks, first-line, use, cml, drug, gleevec

Novartis seeks first-line use for CML drug Gleevec in USA and Europe

Article | 08 July 2002

Print This

Novartis has filed for approval to extend the indications of its chronicmyeloid leukemia drug Glivec/Gleevec (imatinib mesylate) in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in